A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.

ABSTRACT:

Background

Adavosertib (AZD1775) is a first-in-class, selective, small-molecule inhibitor of Wee1.

Objective

The safety, tolerability, pharmacokinetics, and efficacy of adavosertib monotherapy were evaluated in patients with various solid-tumor types and molecular profiles.

Patients and methods

Eligible patients had the following: confirmed diagnosis of ovarian cancer (OC), triple-negative breast cancer (TNBC), or small-cell lung cancer (SCLC); previous treatment for metastatic/recurrent disease; and measurable disease. Patients were grouped into six matched cohorts based on tumor type and presence/absence of biomarkers and received oral adavosertib 175 mg twice a day on days 1-3 and 8-10 of a 21-day treatment cycle.

Results

Eighty patients received treatment i

SUBMITTER: Bauer TM 

PROVIDER: S-EPMC10345044 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature